news.today
Hello · Register today | LoginHello · My Account[—] [33]
World

Australian drug slows Alzheimer's progression by 30 per cent in older patients

Summarised from 2 outlets · Updated 19 Nov, 06:44 · Archive

An Australian-developed drug that blocks cortisol production in the brain slowed Alzheimer's progression by 30 per cent in patients over 75 in a trial of 247 people.

Australian biotech company Actinogen has released results from its phase 2 trial of Emestedastat, a drug developed under the brand name Xanamem that blocks production of the stress hormone cortisol in key areas of the brain. The trial involved 247 patients in Australia and the US with mild to moderate Alzheimer's disease, each taking a daily pill for 36 weeks.

In patients over the median age of 75, representing half the trial group, the drug slowed disease progression by 30 per cent. According to Actinogen, most participants experienced few side effects during the trial period. However, the drug did not record a statistically significant benefit across the overall trial group.

Actinogen chief executive Steven Gourlay said a $10.8 million research and development tax incentive rebate from the federal government had strengthened the company's cash position. The company plans to begin a larger phase 3 trial involving 700 patients in mid-2027, with hopes of bringing the drug to market in 2030.

Australian drug slows Alzheimer's progression by 30 per cent in older patients
Image: The West Australian

Comments (0)

How it is being reported

In this story: Actinogen · Steven Gourlay · Australia · United States

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem · Corrections log